Late-Breaking Preclinical Data: Novel Anti-FasL mAb for Severe Dermatologic Conditions
Time: 9:00 am
day: Day One
Details:
- Discover a novel non-immunosuppressive approach targeting FasL in severe blistering conditions with significant mortality rates
- Explore preclinical efficacy data from validated disease models using proprietary humanised FasL mouse platform
- Understand unique clinical considerations for underserved ‘orphan’ dermatology indications
